Novo Nordisk is betting on a new pipeline of obesity and diabetes drugs as Eli Lilly widens its lead in GLP-1s, including in the growing oral pill market and Medicare-covered obesity treatments.

Sep 25, 2026 - 09:00
 0  0
Novo Nordisk is betting on a new pipeline of obesity and diabetes drugs as Eli Lilly widens its lead in GLP-1s, including in the growing oral pill market and Medicare-covered obesity treatments.

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0